PDL-1TECENTRIQ ATEZOLIZUMAB 阿特珠单抗

Atezolizumab is a PD-L1 inhibitor immunotherapy drug. It blocks the binding of the PD-L1 protein on the surface of tumor cells to immune cell receptors, thereby activating the body’s immune system to attack cancer cells. It is primarily used to treat non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer, and hepatocellular carcinoma, and should be used strictly according to a physician’s instructions.

Mechanism of Action

Blocking the PD-L1 pathway: Tumor cells bind to the PD-1 or B7.1 receptors on immune cells (such as T cells) through the PD-L1 protein, suppressing the immune response. Atezolizumab blocks this pathway and restores T cell activity.

Immune System Activation: After immunosuppression is relieved, T cells can recognize and eliminate cancer cells, achieving an anti-tumor effect.

Indications

Non-small cell lung cancer: For patients with advanced disease with high PD-L1 expression or specific gene mutations.

Small cell lung cancer: Used in combination with chemotherapy as a first-line treatment for patients with extensive-stage disease. Triple-negative breast cancer: In combination with nab-paclitaxel, suitable for patients with PD-L1-positive metastatic disease.
Hepatocellular carcinoma: In combination with the targeted drug bevacizumab, suitable for patients with unresectable or metastatic disease.
Precautions
Pre-treatment evaluation: PD-L1 expression levels in tumor tissue should be measured. For some indications, other biomarkers may be used in combination.
Side effect management:
Common: Fatigue, loss of appetite, nausea, rash, etc.
Severe: Immune pneumonitis, hepatitis, colitis, or endocrine disorders (such as thyroid dysfunction). Seek medical attention promptly.
Contraindications: Contraindicated in patients with allergies to drug ingredients, active autoimmune diseases, or organ transplant recipients.
Dosage instructions
Route of administration: Intravenous infusion. Dosage and frequency will be adjusted by the physician based on the patient’s condition.
Treatment monitoring: Regular imaging assessments and blood tests will be performed to monitor efficacy and side effects.
Patient information: Avoid live vaccines during treatment. Report symptoms such as difficulty breathing, persistent fever, or jaundice to the physician immediately. Note: Atezolizumab is a prescription drug. Before use, consult a healthcare professional. Follow your healthcare professional’s instructions strictly during treatment and receive regular follow-up visits.